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ABSTRACT A database of Prostate Cancer Proteomics has been created by using the results of a proteomic study 
of human prostate carcinoma and benign hyperplasia tissues, and of some human-cultured cell lines (PCP, 
http://ef.inbi.ras.ru). PCP consists of 7 interrelated modules, each containing four levels of proteomic and 
biomedical data on the proteins in corresponding tissues or cells. The first data level, onto which each module 
is based, is a 2DE proteomic reference map where proteins separated by 2D electrophoresis, and subsequently 
identified by mass-spectrometry, are marked. The results of proteomic experiments form the second data level. 
The third level contains protein data from published articles and existing databases. The fourth level is formed 
with direct Internet links to the information on corresponding proteins in the NCBI and UniProt databases. PCP 
contains data on 359 proteins in total, including 17 potential biomarkers of prostate cancer, particularly AGR2, 
annexins, S100 proteins, PRO2675, and PRO2044. The database will be useful in a wide range of applications, 
including studies of  molecular mechanisms of the aetiology and pathogenesis of prostate diseases, finding new 
diagnostic markers, etc.
KEYWORDS proteomics, prostate cancer, digital database
ABBREVIATIONS 2DE—two-dimensional gel electrophoresis, BPH—benign prostate hyperplasia, PCa—prostate 
cancer, PCP—prostate cancer proteomics
INTRODUCTION
The first decade of the post-genome era was marked 
by a rapid development in the field of bioinformatics, 
the extension of major databases (such as NCBI and 
UniProt), and the creation of specialised information 
resources for biomedical research in many countries 
[1–4]. The impressive resources created in Ireland 
(UCD-2DPAGE, http://proteomics-portal.ucd.ie:8082/
cgi-bin/2d/2d.cgi) [2] and India (Human Proteinpedia, 
www.humanproteinpedia.org) [3] make the state of things 
in Russia pale in comparison.
Currently, one of the most important tasks for bio-
medical research is to find efficient prostate cancer 
(PCa) biomarkers which would enable new diagnostic 
methods [5–8]. The fact that in recent years the PCa 
incidence rate has dramatically increased worldwide 
[9, 10], and particularly in Russia, making PCa the most 
frequent male oncological disease in some countries 
[11, 12], is reason enough to pay close attention to this 
disease. In early diagnostics of PCa at the moment it is 
important to establish the presence of one of the most 
studied biomarkers, the so-called Prostate-Specific An-
tigens (PSA), in the blood. The test, however, is known 
to produce a significant number of false-positive and 
false-negative results, leading to the wrong clinical and 
financial outcomes [5, 7]. Therefore, in the U.S. and in 
other Western countries, new PCa biomarkers are be-
ing actively sought, an initiative recently stimulated by 
the development of proteomic and other post-genome 
technologies [6, 8, 13].
Since 2005, the Bach Institute of Biochemistry, 
in collaboration with other research and medical in-
stitutions, has been researching new PCa biomar-
kers by utilising various proteomic technologies [14, 
15]. In 2009, the “Prostate Cancer Proteomics” (PCP, 
http://ef.inbi.ras.ru/) national database was created in 
order to facilitate this research, summarising experi-
mental and referenced published data and providing 
links to several other biomedical Internet databases. 
This paper describes the structure and capabilities of 
the new, extended PCP version.
MATERIALS AND METHODS
Biomaterials— Biopsy and surgical samples of 
prostate  tissues  from  patients  with  PCa  ( n  = 
72) and benign prostatic hyperplasia (BPH,  n  = 
69) were provided by staff members of the Urology Depart-
ment of the Botkin Clinical Hospital (Moscow). Diagnosis 
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was performed using clinical, histological, and immu-
nochemical (PSA level) tests. Histological verification 
was performed via U.S.-controlled transrectal multifo-
cal needle biopsy; up to 18 tissue samples from various 
prostate zones per patient were taken [16, 17]. All PCa 
cases were found to be adenocarcinoma. Gleason score 
was determined by following the standard procedure 
[16, 17].
In parallel tests, we analysed the proteins of the 
РС-3 (АСС 465), DU-145 (ACC 261), and BPH-1 (ACC 
143) cell cultures purchased from the German Col-
lection of Microorganisms and Cell Cultures, as well 
as the proteins of cultured cells of the LNCaP line 
provided by Dr. I. G. Shemyakin (Obolensk National 
Science Centre for Applied Microbiology and Biotech-
nology). The cells were cultured in the RPMI-1640 
medium with HEPES, sodium pyruvate, gentamicine 
and 20% fetal bovine serum (FBS) [18], using cell cul-
ture plastic (Costar, USA and Nunc, Denmark) in a 
СО2-incubator (Sanyo, Japan). In addition, we studied 
proteins from the cultured cells of two lines of human 
rhabdomyosarcoma (А-204 and RD) purchased from 
the Ivanovsky Virology Institute, RAMS, and proteins 
from the cultured normal human myoblasts kindly 
provided by Dr T. B. Krohina [19].
The preparation of protein extracts, their O’Farrell 
2DE fractioning, Coomassie Blue R-250 and silver ni-
trate staining, and 2DE analysis were performed fol-
lowing the techniques described in [20, 21]. In addition, 
we used a 2DE procedure with isoelectric focusing us-
ing IPG-PAGE and Ettan IPGphor 3 kit (GE Health-
care), according to the manufacturer’s protocol. Pro-
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Fig. 1. Main steps in the proteomic study of prostate tissue samples from patients with malignant and benign tumors, as 
well as from several cultured human cell lines.RESEARCH ARTICLES
 VOL. 2  № 4 (7)  2010  | ACTA NATURAE | 97
teins were identified with MALDI-TOF MS and MS/
MS using an Ultraflex instrument (Bruker) at a 336-nm 
UV laser beam in a 500–8000 Da cation mode calibrated 
using reference trypsin autolysis peaks and processed 
with Mascot software, Peptide Fingerprint option (Ma-
trix Science, USA) [21, 22]. The proteins were identi-
fied by matching experimental masses with the masses 
of proteins listed in the NCBI Рrotein and SwissProt/
TrEMBL databases. The accuracy of monoisotopic 
masses measured in the reflection mode calibrated with 
autolytic trypsin peaks was 0.005%, and the accuracy 
of the fragment masses was ±1 Da. Hypothetical pro-
teins identified with MALDI-TOF MS corresponding 
to fragments of the full-size proteins, which are pro-
ducts of corresponding genes, were revealed with MS/
MS. The molecular masses of protein fractions were 
determined using the ultrapure recombinant protein 
sets SM0661 (10–200 kDa) and SM0671 (10–170 kDa) 
(Fermentas). The measurement of the optical density 
of 2DE images and/or their fragments was performed 
following scanning (Epson expression 1680) or digital 
photography (Nikon 2500 or Canon PowerShot A1000 
IS). Digital image processing with densitometry of the 
protein fractions was performed with Melanie Image-
Master, versions 6 and 7 (Genebio).
Data logging and processing for the Prostate Cancer 
Proteomics multilevel database were done with various 
software packages, including MapThis!, Molly Penguin 
Software, Mozilla Firefox, and some Microsoft Office 
applications. A MySQL-based interactive database was 
used which could be updated and modified online using 
any computer with Internet connection. The BIOSTAT 
and Microsoft Office Excel 2003 software packages 
were used for statistical analysis.
RESULTS AND DISCUSSION
According to the conventional proteomics strategy de-
veloped in the late 20th century, the national PCP da-
tabase was created in several consecutive steps which 
involved systematic characterisation of proteins in 
prostate tissue samples obtained from benign and ma-
lignant tumors (Fig. 1) ([23, 24]). Proteins from several 
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Fig. 2. Results of proteomic study of malignant prostate tissue samples.  
A. Typical 2D electrophoregram of proteins from prostate tissue biopsy 
samples with PCa. B. Synthetic 2DE image of proteins from prostate tissue 
biopsy samples with PCa; reference fractions are marked with red ovals. 
Vertical axis: molecular weights.  Horizontal axis: isoelectric points. C. 2D 
protein map constructed from synthetic 2DE image of proteins from prostate 
tissue biopsy samples with PCa; fractions characterized with 2DE are marked 
with blue arrows.98 | ACTA NATURAE |  VOL. 2  № 4 (7)  2010
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cultured human cell lines were studied in parallel ex-
periments (Fig. 1).
The first step was to make series of 2DE protein sam-
ples (50 or more) by fractioning dozens of bioptates or 
prostate tissue samples (from 30 or more patients). Fi-
gure 2A illustrates a typical 2DE of the PCa prostate 
tissue proteins. The 2DE series for cell line proteins 
were created with 20 2DE, taking into account the ho-
mogeneity of the analyte.
The distribution of 2DE protein fractions was re-
gistered and stored as graphic *.tif  files. The images 
of the entire 2DE and (in some cases) their segments 
were produced by scanning and/or digital photogra-
phy. The relevance of the selected 2DE was assessed 
by comparing protein fractioning results using digital 
image matching [23, 24].
The second step was to construct synthetic 2D maps 
of the proteins. 2DE images from each series were 
standardised with Melanie ImageMaster software us-
ing 15 selected reference points corresponding to easily 
identifiable major protein fractions. Figure 2B shows 
reference points on the 2DE images of proteins from 
prostate tissue samples.
Each image was analysed using the Cummings tech-
nique [25] with some modifications [20, 24]. The analysis 
was based on dividing the images into 49 rectangular 
fragments, the sides of which formed six horizontal and 
six vertical standard lines and the sides of the 2DE im-
age itself. The points for plotting the horizontal lines 
were determined by special molecular-weight-marker 
proteins, which were placed on each gel plate before 
fractioning in the second direction (SDS-PAGE). Thus, 
the protein fractions located on the corresponding hori-
zontal lines have identical molecular weights. For plot-
ting the vertical lines, protein markers with previously 
measured pI values were used [20, 24]. As a result, each 
image analyzed consisted of 49 rectangular fragments, 
each usually containing no more than 10 protein frac-
tions (only 4 fragments contained more than 20 frac-
tions). Image fragmenting significantly simplified the 
image comparison and construction of synthetic 2D 
maps.
The described procedure was performed with the 
60 best 2DE images of proteins from BHP samples and 
with 70 2DE images of proteins from PCa samples. The 
comparison of standardised BHP and PCa 2DE images 
showed that the coordinates of more than 95% of pro-
tein fractions were constant. Quantitative or qualita-
tive variations in the coordinates were observed for less 
than 5% of the fractions. The variations could be caused 
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by genetic factors (e.g. single nucleotide polymorphism) 
or a different expression of corresponding genes, as 
well as differences in tissue composition of the samples 
and the pathology’s intensity.
Having made sure that the positions of the majority 
of the protein fractions were constant, we were able 
to construct the 2D maps of prostate tissue proteins 
from patients with BHP and PCa. After that, we per-
formed a fragment-by-fragment comparison of the 2D 
maps constructed. The fraction patterns in BHP and 
PCa maps were found to be quite similar, the differ-
ence being that about 20 fractions present in the PCa 
map were either present in a much smaller amount in 
the BHP map or absent altogether. We paid particu-
lar attention to those fractions in further study, as de-
scribed below. In general, as a result of our analysis, an 
integrated synthetic 2D map of human prostate pro-
teins was constructed that contains more than 200 pro-
tein fractions in the ranges of Mw 8.5–450 kDa and pI 
4.5–11.5 (Fig. 2C). Each fraction was assigned a unique 
seven-digit number; the first four digits representing 
the logarithm of the fraction’s molecular weight, and 
the next three digits representing the value of the iso-
electric point expressed in units described in [20, 24].
The same procedure was applied to construct other 
synthetic maps of proteins from cultured human cell 
lines, although much fewer 2DE images were used for 
those maps.
Table 1. Description of the PCP modules and the number of 
identified proteins by modules.
Modules—synthetic maps of proteins in 
specific objects (fractioning technique)
Proteins 
identified
Prostate biopsy samples, PCa and BPH 
(IEF-PAGE*) 165
LNCaP
(IEF-PAGE*) 60
LNCaP
(IPG-PAGE) 18
PC-3
(IEF-PAGE*) 25
BPH-1
(IEF-PAGE*) 24
Rhabdomyosarcoma
(IEF-PAGE*) 29
Normal human fibroblasts
(IEF-PAGE*) 38
* modification [20]
Thus, each of the constructed maps contained data 
on the electrophoretic properties of the protein frac-
tions (represented by their coordinates) in the corre-
sponding object. These maps were in *.jpg format (with 
a resolution of at least 300 dpi), constituting Level 1 of 
the database. Further studies and analysis of data on 
proteins were based on the information contained in 
the Level 1 maps. Therefore, the synthetic maps rep-
resented original modules enabling the characterizing 
and formalizing of the biochemical properties of the 
proteins studied. There are currently seven modules in 
PCP (Table 1). There is a special panel enabling navi-
gation among the modules. The 2D maps are scaleable, 
and the user can mark certain proteins on the maps 
and create links (buttons) for accessing other levels–
second, third, and fourth–that contain data on the pro-
teins. The database also automatically displays 2D co-
ordinates (along the two fractioning axes) as the cursor 
moves around the map. The general organisation of the 
PCP database is presented in Fig. 3.
The third step in the proteomic study was to identify 
individual protein fractions. The proteins were mainly 
identified by mass-spectrometry: the results are pre-
sented in Table 1.
As Table 1 shows, there is a total of 359 identified 
proteins in PCP. Among them there are many well-
known proteins, such as the enzymes responsible for 
glycolysis (glyceraldehyde-3-phosphate dehydroge-
nase, triose-phosphate isomerase, etc.) and other met-
abolic processes, as well as cytoskeletal (actin, trans-
gelins, etc.) and mitochondrial (porins, superoxide 
dismutase, etc.) proteins. Some of the identified pro-
teins, for instance transgelins [21, 22], were represented 
with several isoforms.
We paid particular attention to the identification 
of the protein fractions which differed qualitatively 
or quantitatively in the prostate tissue samples from 
patients with BHP and PCa. We previously reported 
on the results of identification of two potential PCa 
biomarkers, the proteins AGR2 [14] and Dj-1 [26]. In 
total, we succeeded in identifying 17 potential PCa bi-
omarkers, some of which are new. Table 2 provides a 
short description of the potential PCa biomarkers. For 
example, Fig.4 shows the results of MS identification 
of one of the new biomarkers, protein PRO2675, which 
contains an albumin domain in its primary structure.
For each protein identified (and marked with a “but-
ton” on the 2D map), the second information Level was 
formed, comprising a standardized system of 15 fields 
for the entry of text and graphical data obtained during 
characterization of the corresponding protein fraction. 
In four fields, general information about the protein is 
entered, in the next six fields the identification results 
are entered, and in the other five fields additional in-100 | ACTA NATURAE |  VOL. 2  № 4 (7)  2010
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formation is entered. The filled Level 2 fields for one 
of the potential PCa biomarkers, protein NANS (N-
acetylneuraminic acid phosphate synthase), are shown 
in Fig. 5.
The same protein could be present in more than one 
object. Therefore, within Level 2, one can use the con-
trol panel to create cross-links between identical pro-
teins in different modules. An example of such cross-
referencing for protein Dj-1 is presented in Fig. 6.
Table 2. Potential PCa biomarkers in the “Prostate biopsy samples, PCa and BPH” module and other PCP modules
Unique  
identifier*
Protein (synonyms  
and symbol in PCP)
Numbers in NCBI**  
and Swiss-Prot
Additional information in PCP and refer-
ences***
5653580 Ferritin light chain complex  
(K-(L)F) 182516, P02792 [15]
4785508
(4799550) Chaperonin (HSPD1) 31542947, NP_002147, 
118190, P10809
Found in rhabdomyosarcoma cells;
{Bindukumar B. et al. 2008, 18646040}
4716560
(4756612)
Protein-disulphide isomerase 
(ER60) 7437388, P30101 [15]
4531685 N-acetylneuraminat phosphate 
synthase (NANS)
12652539, AAH00008, 
NP_061819, 605202, 
Q9NR45
Found in rhabdomyosarcoma cells; [15]
4502675 Annexin 2, isophorm 2 (ANXA2-i2) 4757756, NP_004030, 
151740, P07355
{Shiozawa Y. et al. 2008, 18636554; Hastie C. 
et al. 2008, 18211896}
4454692
Unknown protein PRO2675 
containing the albumin domain 
(PRO2675)
7770217 [15]
4447605 Protein 29 of endoplasmic reticu-
lum, isophorm 1 (Erp29)
5803013, NP_006808, 
602287, P30040 {Myung J.K. et al. 2004, 15598346}
4352630 
(4342620) Dj-1 protein (Dj-1) 50513593, 1SOA_A, 
606324, Q99497 {Bindukumar B. et al. 2008, 18646040}
4356607 
(4344615)
Dj-1 protein, electrophoretic 
isophorm (Dj-1-ei) 31543380
4336712 
(4301795)
Prostatic binding protein (neu-
ropolypeptide h3, PEBP1)
21410340, AAH31102, 
604591, P30086
[15]; {Li et al. 2008, 18161940; Woods 
Ignatoski K.M. et al. 2008, 18722266}
4286750 
(4290620)
NM23B-protein, nucleoside phos-
phate kinase B
4505409, NP_002503, 
156491, P22392 {Johansson B. et al. 2006, 16705742}
4255880
Unnamed protein (NEDO human 
cDNA sequencing project, tissue 
type = “testis”) (NEDO)
21758704, BAC05360
4204630 Fatty acid binding protein, iso-
phorm 5 (E-FABP)
30583737, AAP36117, 
605168, Q01469 [15]; {Morgan E.A. et al. 2008, 18360704}
4279900 AGR2 (AGR2) 37183136, AAQ89368, 
606358. Q4JM47
[14, 15]; {Zhang J.S. et al. 2005, 15834940; 
weitzig D.R. et al. 2007, 17694278}
41811130 Hystone H3, 3A family (H3f3a) 55665435 [15]
4161675
Unknown protein PRO2044 
containing the albumin domain 
(PRO2044)
6650826 [15]
4021610 S100 calcium binding protein A11 
(S100A11)
12655117, AAH01410, 
603114, P31949
{Rehman I. et al. 2004, 15668896; Schaefer 
K.L. et al. 2004, 15150091}
* Numbers in the “LNCaP (IEF-2DE Modification)” module are given in parenthesis
** Numbers from the NCBI databases are given in the following order: Protein, Genbank and/or Nucleotide, OMIM
*** Publications listed in the References section of this article are given in square brackets; publications from the PubMed database 
are given in curly brackets.
Note: a new potential biomarkers are shown in bold
The majority of the 359 identified fractions were 
well-known proteins (and/or their electrophoretic iso-
phorms) described in the literature and various data-
bases. Some information on those proteins, relating to 
the PCP scope, constituted the third information Level 
of the database. Level 3 is a standardized system of 23 
fields for the entry of text and graphical data. In twelve 
fields information about the protein is entered, in the 
next six fields information about the gene coding for RESEARCH ARTICLES
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Start-end Experimental 
Mw
Calculated 
Mw
Peptide  
sequence
1 - 16 1706.77 1705.82 MPADLPSLAADFVESK + 
Oxidation (M)
27 - 39 1639.82 1638.79 DVFLGMFLYEYAR + 
Oxidation (M)
76 - 92 2045.05 2044.09 VFDEFKPLVEEPQNLIK
106 - 113 960.52 959.56 FQNALLVR
118 - 131 1511.74 1510.84 VPQVSTPTLVEVSR
249 - 263 1763.73 1762.77 AVMDDFAAFVEKCCK + 
Oxidation (M)
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Fig. 4. Results of mass-spectrometric identification of the PRO 2675 protein.
A. Mass-spectrum of tryptic peptides. (1) MALDI-TOF MS data. (2) Peptide identification by Mascot.
B. Mass-spectrum of one of the tryptic peptides (1) MALDI-TOF MS data. (2) Peptide identification by Mascot.
C. Amino acid sequence of the PRO 2675 protein (records AAF69644.1 GI:7770217 in the NCBI Protein database); amino acid 
residues of the tryptic peptides are printed in red; the peptide's whose sequence was identified by MALDI-TOF MS/MS and is 
highlighted in grey; the sites corresponding to the albumin domain are underlined.102 | ACTA NATURAE |  VOL. 2  № 4 (7)  2010
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the protein is entered, and in the next three fields in-
formation about the protein’s polymorphism is entered. 
In the other fields, selected references to publications 
about the general properties of the proteins, as well as 
its oncological properties, are entered (Fig. 7).
The Level 3 text fields can contain hyperlinks to var-
ious Internet databases, such as NCBI’s Protein, OMIM 
and PubMed, and SwissProt. This feature allowed the 
creation of the fourth information Level, providing 
the user with prompt access to international databases 
containing, in particular, the results of human genome 
sequencing.
The PCP database is an interactive MySQL-based 
web resource located at http://ef.inbi.ras.ru and can 
Fig. 5. Level 2 fields for the NANS protein.
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Supplementary identification information
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Method
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Mascot (Matrix Science, USA) search 
results 
Figure 
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Edit
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Fig. 6. Control 
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module. 
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Module Point Link  Disconnect 
LNCaP (IPG-2DE) 4301630.Dj-1  Link Disconnect
LNCaP (IEF-2DE modification) 4342635.Dj-1 Link Disconnect
Rhabdomyosarcoma 4342690.DJ-1  Link Disconnect
PC3 4342630.DJ-1 Link Disconnect
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Fig. 7. Level 3 
fields for specially 
selected references 
to publications on 
the AGR2 protein.
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be accessed from any computer connected to the In-
ternet using the Mozilla Firefox and Microsoft Internet 
Explorer browsers. There are three access permission 
categories: “Guest,” “Manager,” and “Administrator,” 
each giving certain rights for working with PCP. In 
particular, users with “Manager” access permission can 
make entries into and correct the Level 2 and 3 fields, 
while users with the “Administrator” category access 
permission, have the ability to expand the database by 
creating new modules and new functional elements. Us-
ers with “Guest” access can browse all fields but cannot 
edit them.
In conclusion, our work resulted in the creation of an 
original multi-module national database entitled “Pros-
tate Cancer Proteomics,” which summarizes data on 
the proteins in prostate tissue collected from patients 
with BHP and PCa, as well as on proteins in several hu-
man cell lines. This is very promising in the further use 
of proteomic and other biochemical data. We are hope-
ful that the PCP database will be useful to biochemists 
and other biomedical scientists, making  their research 
on PCa more efficient. 
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